Literature DB >> 19885031

Deficiency of iNOS Does Not Prevent Isoproterenol-induced Cardiac Hypertrophy in Mice.

Hye-Na Cha1, Geu-Ru Hong, Yong-Woon Kim, Jong-Yeon Kim, Jin-Myoung Dan, So-Young Park.   

Abstract

We investigated whether deficiency of inducible nitric oxide synthase (iNOS) could prevent isoproterenol-induced cardiac hypertrophy in iNOS knockout (KO) mice. Isoproterenol was continuously infused subcutaneously (15 mg/kg/day) using an osmotic minipump. Isoproterenol reduced body weight and fat mass in both iNOS KO and wild-type mice compared with saline-infused wild-type mice. Isoproterenol increased the heart weight in both iNOS KO and wild-type mice but there was no difference between iNOS KO and wild-type mice. Posterior wall thickness of left ventricle showed the same tendency with heart weight. Protein level of iNOS in the left ventricle was increased in isoproterenol-infused wild-type mice. The gene expression of interleukin-6 (IL-6) and transforming growth factor-beta (TGF-beta) in isoproterenol-infused wild-type was measured at 2, 4, 24, and 48-hour and isoproterenol increased both IL-6 (2, 4, 24, and 48-hour) and TGF-beta (4 and 24-hour). Isoproterenol infusion for 7 days increased the mRNA level of IL-6 and TGF-beta in iNOS KO mice, whereas the gene expression in wild-type mice was not increased. Phosphorylated form of extracellular signal-regulated kinases (pERK) was also increased by isoproterenol at 2 and 4-hour but was not increased at 7 days after infusion in wild-type mice. However, the increased pERK level in iNOS KO mice was maintained even at 7 days after isoproterenol infusion. These results suggest that deficiency of iNOS does not prevent isoproterenol-induced cardiac hypertrophy and may have potentially harmful effects on cardiac hypertrophy.

Entities:  

Keywords:  Cardiac hypertrophy; Inducible nitric oxide synthase; Isoproterenol

Year:  2009        PMID: 19885031      PMCID: PMC2766730          DOI: 10.4196/kjpp.2009.13.3.153

Source DB:  PubMed          Journal:  Korean J Physiol Pharmacol        ISSN: 1226-4512            Impact factor:   2.016


  34 in total

Review 1.  Nitric oxide and cardiac function.

Authors:  R A Kelly; J L Balligand; T W Smith
Journal:  Circ Res       Date:  1996-09       Impact factor: 17.367

Review 2.  The beta-adrenergic receptors and the control of adipose tissue metabolism and thermogenesis.

Authors:  S Collins; R S Surwit
Journal:  Recent Prog Horm Res       Date:  2001

3.  Essential role of inducible nitric oxide synthase in monophosphoryl lipid A-induced late cardioprotection: evidence from pharmacological inhibition and gene knockout mice.

Authors:  L Xi; N C Jarrett; M L Hess; R C Kukreja
Journal:  Circulation       Date:  1999-04-27       Impact factor: 29.690

4.  Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in gp130-mediated cardiac hypertrophy.

Authors:  H Kodama; K Fukuda; J Pan; M Sano; T Takahashi; T Kato; S Makino; T Manabe; M Murata; S Ogawa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-10       Impact factor: 4.733

5.  Absence of inducible nitric oxide synthase modulates early reperfusion-induced NF-kappaB and AP-1 activation and enhances myocardial damage.

Authors:  Basilia Zingarelli; Paul W Hake; Zequan Yang; Michael O'Connor; Alvin Denenberg; Hector R Wong
Journal:  FASEB J       Date:  2002-03       Impact factor: 5.191

6.  Increased superoxide radical with a decrease in vascular endothelial growth factor and inducible nitric oxide synthase level leads to the progression of left ventricular hypertrophy in a pressure-overload rat heart model.

Authors:  Kaiqiang Ji; Masahito Minakawa; Kozo Fukui; Yasuyuki Suzuki; Ikuo Fukuda
Journal:  Ann Thorac Cardiovasc Surg       Date:  2008-08       Impact factor: 1.520

7.  Cardiac hypertrophy-induced changes in mRNA levels for TGF-beta 1, fibronectin, and collagen.

Authors:  F J Villarreal; W H Dillmann
Journal:  Am J Physiol       Date:  1992-06

8.  Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure. Marked upregulation of genes encoding extracellular matrix components.

Authors:  M O Boluyt; L O'Neill; A L Meredith; O H Bing; W W Brooks; C H Conrad; M T Crow; E G Lakatta
Journal:  Circ Res       Date:  1994-07       Impact factor: 17.367

Review 9.  Return to the fetal gene program protects the stressed heart: a strong hypothesis.

Authors:  Mitra Rajabi; Christos Kassiotis; Peter Razeghi; Heinrich Taegtmeyer
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

Review 10.  Cardiac hypertrophy induced by sustained beta-adrenoreceptor activation: pathophysiological aspects.

Authors:  Oleg E Osadchii
Journal:  Heart Fail Rev       Date:  2007-03-27       Impact factor: 4.654

View more
  4 in total

1.  Metformin Inhibits Isoproterenol-induced Cardiac Hypertrophy in Mice.

Authors:  Hye-Na Cha; Jung Hyun Choi; Yong-Woon Kim; Jong-Yeon Kim; Myun-Whan Ahn; So-Young Park
Journal:  Korean J Physiol Pharmacol       Date:  2010-12-31       Impact factor: 2.016

2.  Inhibition of Inducible Nitric Oxide Synthase Attenuates Monosodium Urate-induced Inflammation in Mice.

Authors:  Tae-Jin Ju; Jin-Myoung Dan; Young-Je Cho; So-Young Park
Journal:  Korean J Physiol Pharmacol       Date:  2011-12-27       Impact factor: 2.016

3.  Mouse models for the study of postnatal cardiac hypertrophy.

Authors:  A Del Olmo-Turrubiarte; A Calzada-Torres; G Díaz-Rosas; I Palma-Lara; R Sánchez-Urbina; N A Balderrábano-Saucedo; H González-Márquez; P Garcia-Alonso; A Contreras-Ramos
Journal:  Int J Cardiol Heart Vasc       Date:  2015-03-06

4.  Protective Role for LPA3 in Cardiac Hypertrophy Induced by Myocardial Infarction but Not by Isoproterenol.

Authors:  Lin Cai; Guangpu Fan; Fang Wang; Si Liu; Tiewei Li; Xiangfeng Cong; Jerold Chun; Xi Chen
Journal:  Front Physiol       Date:  2017-05-30       Impact factor: 4.566

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.